Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
(1) To evaluate the efficacy of suvorexant compared with placebo in improving insomnia, as measured by change from baseline in PSG-derived total sleep time (TST), at Week 4. (2) To evaluate the safety and tolerability of suvorexant for up to 4 weeks of treatment.
Critère d'inclusion
- Insomnia